- Home
- INBK vs CRVS Comparison
INBK vs CRVS Comparison
Compare INBK & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBK
- CRVS
- Stock Information
- Founded
- INBK 1999
- CRVS 2014
- Country
- INBK United States
- CRVS United States
- Employees
- INBK N/A
- CRVS N/A
- Industry
- INBK Major Banks
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- INBK Finance
- CRVS Health Care
- Exchange
- INBK Nasdaq
- CRVS Nasdaq
- Market Cap
- INBK 228.1M
- CRVS 257.0M
- IPO Year
- INBK N/A
- CRVS 2016
- Fundamental
- Price
- INBK $23.99
- CRVS $2.86
- Analyst Decision
- INBK Buy
- CRVS Strong Buy
- Analyst Count
- INBK 4
- CRVS 5
- Target Price
- INBK $40.50
- CRVS $12.63
- AVG Volume (30 Days)
- INBK 36.0K
- CRVS 726.0K
- Earning Date
- INBK 04-23-2025
- CRVS 05-05-2025
- Dividend Yield
- INBK 1.01%
- CRVS N/A
- EPS Growth
- INBK 203.16
- CRVS N/A
- EPS
- INBK 2.88
- CRVS N/A
- Revenue
- INBK $117,652,000.00
- CRVS N/A
- Revenue This Year
- INBK $3.03
- CRVS N/A
- Revenue Next Year
- INBK $16.38
- CRVS N/A
- P/E Ratio
- INBK $8.25
- CRVS N/A
- Revenue Growth
- INBK 39.44
- CRVS N/A
- 52 Week Low
- INBK $22.22
- CRVS $1.30
- 52 Week High
- INBK $43.26
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- INBK 32.03
- CRVS 31.75
- Support Level
- INBK $22.22
- CRVS $2.56
- Resistance Level
- INBK $27.24
- CRVS $3.31
- Average True Range (ATR)
- INBK 1.18
- CRVS 0.35
- MACD
- INBK -0.17
- CRVS -0.07
- Stochastic Oscillator
- INBK 26.09
- CRVS 24.02
Stock Price Comparison Chart: INBK vs CRVS
About INBK First Internet Bancorp
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking/treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).